LY 329722
Latest Information Update: 23 Jan 2007
At a glance
- Originator Eli Lilly and Company; Shionogi
- Class Anti-inflammatories
- Mechanism of Action Phospholipase A2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Reperfusion injury
Most Recent Events
- 22 May 2001 Preclinical development for Reperfusion injury in Japan (Unknown route)